Timo Strandberg

Prof. Timo Strandberg


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in The Lancet
Verified
Journal Article
Closed access
TNTiia Ngandu
Tiia Ngandu
JLJenni Lehtisalo
Jenni Lehtisalo
ASAlina Solomon
Alina Solomon
ELEsko Levälahti
Esko Levälahti
SASatu Ahtiluoto
Satu Ahtiluoto
MKMiia Kivipelto
Miia Kivipelto

1 April 2018 in The Lancet
Verified
Journal Article
Open access
AWAngela M Wood
Angela M Wood
SKStephen Kaptoge
Stephen Kaptoge
ABAdam S Butterworth
Adam S Butterworth
PWPeter Willeit
Peter Willeit
SWSamantha Warnakula
Samantha Warnakula
EGEmerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group
Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th-95th percentile 1·04-13·5]) from 71 011 participants from 37 studies. In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10-1·17), coronary disease excluding myocardial infarction (1·06, 1·00-1·11), heart failure (1·09, 1·03-1·15), fatal hypertensive disease (1·24, 1·15-1·33); and fatal aortic aneurysm (1·15, 1·03-1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91-0·97). In comparison to those who reported drinking >0-≤100 g per week, those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.

3 October 2019 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
EDE. Dent
E. Dent
JMJ. E. Morley
J. E. Morley
ACA. J. Cruz-Jentoft
A. J. Cruz-Jentoft
LWL. Woodhouse
L. Woodhouse
LRL. Rodríguez-Mañas
L. Rodríguez-Mañas
BVB. Vellas
B. Vellas
The task force of the International Conference of Frailty and Sarcopenia Research (ICFSR) developed these clinical practice guidelines to overview the current evidence-base and to provide recommendations for the identification and management of frailty in older adults.

18 January 2013 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
MKMiia Kivipelto
Miia Kivipelto
ASAlina Solomon
Alina Solomon
SASatu Ahtiluoto
Satu Ahtiluoto
TNTiia Ngandu
Tiia Ngandu
JLJenni Lehtisalo
Jenni Lehtisalo
HSHilkka Soininen
Hilkka Soininen

1 November 2005 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
NSN. Savikko
N. Savikko
PRP. Routasalo
P. Routasalo
RTR.S. Tilvis
R.S. Tilvis
TSTimo Strandberg
Timo Strandberg
KPK.H. Pitkälä
K.H. Pitkälä

29 March 2019 in Circulation Research
Verified
Journal Article
Closed access
PDF file
ABAthanase Benetos
Athanase Benetos
MPMirko Petrovic
Mirko Petrovic
TSTimo Strandberg
Timo Strandberg
The prevalence of arterial hypertension, particularly systolic hypertension, is constantly rising worldwide. This is mainly the clinical expression of arterial stiffening as a result of the population’s aging. Chronic elevation in blood pressure represents a major risk factor not only for cardiovascular morbidity and mortality but also for cognitive decline and loss of autonomy later in life. Clinical evidence obtained in community-dwelling older people with few comorbidities and preserved autonomy supports the beneficial effects of lowering blood pressure in older hypertensive subjects even after the age of 80 years. However, observational studies in frail older individuals treated for hypertension have shown higher morbidity and mortality rates compared with those with lower blood pressure levels. Clearly, in very old subjects, the therapeutic strategy of one size fits all cannot be applied because of the enormous functional heterogeneity in these individuals. Geriatric medicine proposes taking into account the function/frailty/autonomy status of older people. In the present review, we propose to adapt the antihypertensive treatment using an easy-to-apply visual numeric scale allowing the identification of 3 different patient profiles according to the functional status and autonomy for activities of daily living. For the preserved function profile, strategies should be those proposed for younger old adults. For the loss of function/preserved activities of daily living’ profile, a more detailed geriatric assessment is needed to define the benefit/risk balance as well as requirements for the tailoring of the various therapeutic strategies. Lastly, for the loss of function and altered activities of daily living’ profile, therapeutic strategies should be thoroughly reassessed, including deprescribing (when considered appropriate). In the near future, controlled trials are necessary for the most frail older subjects (ie, in those systematically excluded from previous clinical trials) to gain stronger evidence regarding the benefits of the various therapeutic strategies.